A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
The purpose of this study is to compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic therapy.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
Inclusion Criteria:
Exclusion Criteria:
Buenos Aires, Buenos Aires C1181ACH, Argentina
Caba, Buenos Aires 1221, Argentina
Capital Federal, Buenos Aires C1264AAA, Argentina
Westmead Nsw, New South Wales 2145, Australia
Prahan, Victoria 3004, Australia
Salvador - Ba, Estado de Bahia 40050-410, Brazil
Hyderabad, Andhra Pradesh 500082, India
Torrette -Ancona, 60020, Italy
Kashiwa-shi, Chiba 277-0882, Japan
Kawasaki-shi, Kanagawa 2138587, Japan
Higashinari-ku, Osaka 5378511, Japan
Sunto-gun, Shizuoka 411-8777, Japan
Chuo-Ku, Tokyo 104-0045, Japan
Minato-ku, Tokyo 105-0001, Japan
Musashino-shi, Tokyo 180-0023, Japan
Shimonoseki-shi, Yamaguchi 7500061, Japan
Nishinomiya-shi, 6638501, Japan
D.f., Mexico City 06720, Mexico
D.f., Mexico City 14140, Mexico
Distrito Federal, Mexico City 06760, Mexico
Observatory, Cape Town, Western Cape 7925, South Africa
Kyunggi-do, 463-707, South Korea
Tainan R.o.c., 70403, Taiwan